INO-1001
Modify Date: 2024-01-02 09:27:37
INO-1001 structure
|
Common Name | INO-1001 | ||
|---|---|---|---|---|
| CAS Number | 501364-82-5 | Molecular Weight | 439.52700 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H25N3O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of INO-1001INO-1001 is a potent and selective Poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 0.05-1 μM. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death[1]. INO-1001 has anti-tumor effects[2]. |
| Name | N-[3-(4-Morpholinyl)propyl]-5-oxo-6,11-dihydro-5H-indeno[1,2-c]is oquinoline-9-sulfonamide |
|---|---|
| Synonym | More Synonyms |
| Description | INO-1001 is a potent and selective Poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 0.05-1 μM. INO-1001 is a potent enhancer of radiation sensitivity and enhances radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death[1]. INO-1001 has anti-tumor effects[2]. |
|---|---|
| Related Catalog | |
| Target |
PARP:0.05-1 μM (IC50) |
| References |
| Molecular Formula | C23H25N3O4S |
|---|---|
| Molecular Weight | 439.52700 |
| Exact Mass | 439.15700 |
| PSA | 100.14000 |
| LogP | 3.92180 |
|
~54%
INO-1001 CAS#:501364-82-5 |
| Literature: Inotek Pharmaceutical, Corp. Patent: US2006/19980 A1, 2006 ; Location in patent: Page/Page column 31-33; 54 ; |
|
~42%
INO-1001 CAS#:501364-82-5 |
| Literature: INOTEK PHARMACEUTICALS CORPORATION Patent: WO2005/82368 A1, 2005 ; Location in patent: Page/Page column 60; 86-87 ; |
|
~%
INO-1001 CAS#:501364-82-5 |
| Literature: Jagtap, Prakash G.; Baloglu, Erkan; Southan, Garry J.; Mabley, Jon G.; Li, Hongshan; Zhou, Jing; Van Duzer, John; Salzman, Andrew L.; Szabo, Csaba Journal of Medicinal Chemistry, 2005 , vol. 48, # 16 p. 5100 - 5103 |
|
~%
INO-1001 CAS#:501364-82-5 |
| Literature: Jagtap, Prakash G.; Baloglu, Erkan; Southan, Garry J.; Mabley, Jon G.; Li, Hongshan; Zhou, Jing; Van Duzer, John; Salzman, Andrew L.; Szabo, Csaba Journal of Medicinal Chemistry, 2005 , vol. 48, # 16 p. 5100 - 5103 |
|
~%
INO-1001 CAS#:501364-82-5 |
| Literature: Jagtap, Prakash G.; Baloglu, Erkan; Southan, Garry J.; Mabley, Jon G.; Li, Hongshan; Zhou, Jing; Van Duzer, John; Salzman, Andrew L.; Szabo, Csaba Journal of Medicinal Chemistry, 2005 , vol. 48, # 16 p. 5100 - 5103 |
![5-oxo-6,11-dihydroindeno[1,2-c]isoquinoline-9-sulfonyl chloride structure](https://www.chemsrc.com/caspic/068/501364-67-6.png)
![6,11-dihydroindeno[1,2-c]isoquinolin-5-one structure](https://www.chemsrc.com/caspic/321/109722-74-9.png)
![(+/-)-11-hydroxy-5,6-dihydro-5-oxo-11H-indeno[1,2-c]isoquinoline structure](https://www.chemsrc.com/caspic/036/5291-20-3.png)
| 9-[N-(3-[morpholin-4-yl]propyl)-aminosulphonyl]-5,6-dihydro-5-oxo-11H-indeno[1,2-c]isoquinoline |
| inotec indeno[1,2c]isoquinoline |
| 9H-Xanthene,9-[bis(4-methoxyphenyl)methylene] |
| 9-[N-(3-[morpholino-4-yl]propyl)-aminosulphonyl]-5,6-dihydro-5-oxo-11H-indeno-[1,2-c]isoquinoline |
| 9-<Bis-(4-methoxy-phenyl)-methylen>-xanthen |